Recombinant IL-12, IL-23 (Ustekinumab Biosimilar) antibody

Catalog No. ABIN7795099

The Mouse Monoclonal anti-IL-12, IL-23 (Ustekinumab Biosimilar) antibody (ABIN7795099) specifically detects IL-12, IL-23 (Ustekinumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant IL-12, IL-23 (Ustekinumab Biosimilar) antibody (ABIN7795099)

Target: IL-12, IL-23 (Ustekinumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL-12, IL-23 (Ustekinumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-IL-12, IL-23 (Ustekinumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody

Characteristics: What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human IL-12 / IL-23

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for IL-12, IL-23 (Ustekinumab Biosimilar)

Target: IL-12, IL-23 (Ustekinumab Biosimilar)

Alternative Name: Ustekinumab Biosimilar

Target Type: Biosimilar